Welcome to CDC stacks | Latent tuberculosis infection; a guide for primary health care providers - 5879 | Stephen B. Thacker CDC Library collection
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
Clear All Simple Search
Advanced Search
Latent tuberculosis infection; a guide for primary health care providers
  • Published Date:
Filetype[PDF-714.49 KB]

  • Corporate Authors:
    National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (U.S.), Division of Tuberculosis Elimination. ; New Jersey Medical School, Global Tuberculosis Institute. ;
  • Description:
    List of abbreviations -- Introduction -- Targeted testing for tuberculosis -- Diagnosis of latent TB infection (LTBI) -- Treatment of latent TB infection -- Appendix A: Sample TB Risk Assessment Tool -- Appendix B: identifying persons from high-risk countries -- Appendix C: Administration and measurement of the TST -- Appendix D: Sample TST and treatment documentation forms -- Resources -- References

    "This guide is intended for primary care providers who care for individuals and populations who may be at risk for infection with Mycobacterium tuberculosis. Latent tuberculosis infection (LTBI) is the presence of Mycobacterium tuberculosis in the body without signs and symptoms, or radiographic or bacteriologic evidence of tuberculosis (TB) disease. Approximately one-third of the world's population is infected with M. tuberculosis. In the United States, an estimated 9-14 million people have LTBI. Without treatment, approximately 5-10% of persons with LTBI will progress to TB disease at some point in their lifetime. Identifying and treating those at highest risk for TB disease will help move toward elimination of the disease. Primary care providers play a key role in achieving the goal of TB elimination because of their access to high-risk populations. Guidelines for testing and treating LTBI were released by the Centers for Disease Control and Prevention (CDC) and the American Thoracic Society (ATS). They can be found in the June 9, 2000 issue of Morbidity and Mortality Weekly Report (MMWR), entitled Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection. Most recently, recommendations for the use of interferon-gamma release assays (IGRAs) were released in the June 25, 2010 issue of Morbidity and Mortality Weekly Report (MMWR), entitled Updated Guidelines for Using Interferon Gamma Release Assays to Detect Mycobacterium Tuberculosis Infection. References for these guidelines and updates can be found on page 32. This document is not meant to be used as a substitute for the guidelines, but rather as a ready and useful reference that highlights the main points of those guidelines." - p. 1

  • Supporting Files:
    No Additional Files
No Related Documents.
You May Also Like: